Question 1

Why did everything stop at six months?

Accepted Answer

★ Because that is the shape of the curve, in every trial, for every drug in this class. STEP-1 fell steeply for about 20 weeks, slowed markedly from week 20 to week 60, and was near flat by the end, finishing at 14.9% at week 68. SURMOUNT-1 traced the same S: fast early, slower through months 6 to 12, flatter to the end at 20.9% on the top dose. STEP-5 carried it to two years and found most of what came off after month 12 was small, settling around 15.2% below baseline. ⚠ So a stall at month six is the published trajectory, not a malfunction. ⛔ One pattern IS worth raising with a clinician rather than waiting out: stalling early at a low starting BMI, having lost only a few percent. That is a different question about whether the drug is the right tool for you, not a plateau.

Question 2

Have I built a tolerance to it?

Accepted Answer

⛔ No, and there is a clean experiment that settles it. Tachyphylaxis would mean the receptors stopped answering the same dose — in which case people who kept taking the drug could not keep losing. They do. In STEP-4, those who continued semaglutide from week 20 to week 68 lost a further 7.9%, while those moved to placebo regained 6.9% over the identical window. SURMOUNT-4 repeated the result on tirzepatide: continuing meant another 5.5% off, switching to placebo meant about 14% back on. ★ Two arms, same starting point, opposite directions — that is not a drug whose effect has worn out. ⚠ What is actually happening is arithmetic: a lighter body burns less, so the deficit that worked at the start eventually closes. The flat line is the drug holding what you lost.

Question 3

Will going up a dose restart it?

Accepted Answer

★ Often, if you are still climbing the ladder. There is a real dose-response: SURMOUNT-1 recorded 15.0%, 19.5% and 20.9% at the 5, 10 and 15 mg tirzepatide doses, and the STEP program found 2.4 mg semaglutide beat both 1.0 mg and 0.5 mg. So stalling at a middle rung frequently resolves at the next one. ⛔ If you are already at the label maximum, the honest answer changes: the trials cannot tell you that going higher helps, because higher was not tested. A 7.2 mg semaglutide arm produced only modestly more loss than 2.4 mg and more stomach trouble with it. ⚠ Before escalating, the cheaper questions are whether you have actually held the current dose long enough, whether doses have been missed, and whether the eating and activity that the trials paired with the drug are still in place.

Question 4

Would switching to the other drug break the stall?

Accepted Answer

★ The evidence does favor tirzepatide, and by less than the forums suggest. Head to head in type 2 diabetes, SURPASS-2 put tirzepatide 15 mg at 12.9% against semaglutide 1.0 mg at 6.2% over 40 weeks. Across the obesity programs — different trials, so read them as indicative rather than matched — SURMOUNT-1's top dose reached 20.9% at 72 weeks against STEP-1's 14.9% at 68. ⚠ For someone stalled near the average on semaglutide, a switch might plausibly add several percentage points of total loss. It will not restart the steep early phase, and expecting that is where disappointment comes from. ⛔ The practical costs are real: re-titration from the bottom rung, the stomach side effects that come with it, a fresh prior authorization, and whatever supply looks like at your new dose.

Question 5

I am barely responding — should I stop?

Accepted Answer

★ Not on the strength of three months, because the trials show a long tail. By week 72 in SURMOUNT-1, 91% on the top dose had lost at least 5% and 57% at least 20% — but the figures at week 24 were far lower, meaning much of that response arrived between months 6 and 18. STEP-1 showed the same late accumulation, with 86% reaching 5% by week 68. ⚠ The important finding for anyone discouraged at month three: being near flat at week 12 does not reliably predict where you land at week 68. The 5%-at-12-weeks checkpoint used in protocols is a prompt to review, not a stop rule. ★ Forum reports of breakthrough at months 6 to 9 line up with the trial curves, and often coincide with reaching the next dose step rather than with anything the person changed.

Question 6

Did my compounded vial go weak, or is this just the plateau?

Accepted Answer

⚠ You cannot tell these apart from the scale, and no head-to-head trial of compounded against brand at the same dose exists to help you. What you can do is compare against the brand trajectory: STEP-1's rate slowed sharply between weeks 20 and 60 on fully potent drug, and SURMOUNT-1 flattened between months 9 and 17. If you stall at month six on a compounded product, that timing is entirely normal even if the vial is perfect. ★ There is one signal that does separate them, and it is not the scale — it is appetite. A genuine potency drop tends to bring back hunger and food preoccupation within days of a dose. A natural plateau leaves appetite suppressed while the scale sits still. ⛔ Stalled with appetite still controlled is a different problem from stalled with hunger roaring back.

Question 7

If I stop at a plateau, does it all come back?

Accepted Answer

⛔ Most of it, and the withdrawal trials are unusually consistent about it. The STEP-1 extension followed people for one year after semaglutide and its behavioral support were withdrawn, and found they regained about two-thirds of what they had lost, with the cardiometabolic improvements drifting back toward baseline alongside. STEP-4 isolated it more cleanly: switch to placebo at week 20 and regain 6.9% by week 68, or continue and lose another 7.9%. SURMOUNT-4 on tirzepatide found the same split — roughly 14% back on placebo against a further 5.5% off on drug. ★ The reframe that follows is the important one: the plateau is not the drug failing, it is the drug holding. Stopping is the event associated with regain, not plateauing. ⚠ Which is why this is generally framed as long-term treatment rather than a course you complete.

Question 8

Could I still be losing fat while the scale sits still?

Accepted Answer

★ Yes, and the body-composition data say the scale is a blunt instrument. In the DXA substudy inside STEP-1, people who lost about 15% of body weight shed roughly 61% of it as fat and 39% as lean tissue — and because so much fat went, the share of the body that was fat still fell. ⚠ If you are lifting, you can sit in a stretch where lean tissue holds or rebuilds while fat keeps coming off, which shows up as a flat scale, a falling waist measurement and looser clothes at the same time. ★ The levers that bias the split toward fat are the familiar ones: protein around 1.2-1.6 g per kg daily and two or three resistance sessions a week. ⛔ The practical test is simple — if the tape and the clothes are moving while the scale is not, the plateau is in your scale rather than your body.

Question 9

Does tightening up the diet and training actually help?

Accepted Answer

★ Yes, and one trial was built to measure exactly that. SURMOUNT-3 took adults through a 12-week intensive lifestyle program, kept those who had already lost at least 5%, then randomized them for 72 weeks to either tirzepatide or a placebo. The drug arm lost a further 18.4% on top of what the lifestyle phase had achieved — about 26.6% in total — while the placebo arm put 2.5% back on. ⚠ The point that gets missed: every headline trial number in this class assumes a lifestyle co-intervention. The STEP program paired semaglutide with a 500-calorie deficit, 150 minutes a week of activity and monthly counseling, and its results describe that combination, not the drug by itself. ★ So people who stall at month six after quietly dropping the deficit, the activity or the logging are comparing themselves to a number they are no longer running the protocol for.

Question 10

How long does a stall normally last?

Accepted Answer

⚠ No trial tracked individual stalls, so anyone quoting you a precise number is inventing it. What the trials do show is the group curve flattening and then continuing: STEP-1 slowed sharply between weeks 20 and 60 while still finishing at 14.9%, and STEP-5 kept producing small losses past month 12 toward roughly 15.2% at two years. ★ More useful is when people crossed their thresholds. In SURMOUNT-1 the 5%, 10%, 15% and 20% crossings were spread right across the 72 weeks, with a substantial share arriving in months 12 to 17 rather than in the first half. ★ The rough shape reported in the forums matches that: a few weeks is ordinary, two to three months is not unusual, and beyond about four months at the same dose with your habits genuinely intact is the point where most clinicians revisit dose, drug or plan.

GLP-1 Plateaus: 10 Questions About Why the Scale Stopped

Q1.Why did everything stop at six months?

Q2.Have I built a tolerance to it?

Q3.Will going up a dose restart it?

Q4.Would switching to the other drug break the stall?

Q5.I am barely responding — should I stop?

Q6.Did my compounded vial go weak, or is this just the plateau?

Q7.If I stop at a plateau, does it all come back?

Q8.Could I still be losing fat while the scale sits still?

Q9.Does tightening up the diet and training actually help?

Q10.How long does a stall normally last?

References

Questions and answers